April 21 (Reuters) - AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met the main goal of a late-stage ...

Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...

Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with IgAN in I CAN phase III trial: Cambridge, UK Wednesday, April 22 ...

Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare ...

"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...

AstraZeneca AZN announced positive results from an interim analysis of the ongoing late-stage I CAN study, which evaluated ...

AstraZeneca PLC announced the successful completion of Phase III trials for Ultomiris, achieving the primary endpoint by ...

AstraZeneca (AZN) stock is in focus as the company plans to seek accelerated approval for Ultomiris in IgA nephropathy after ...

Ultomiris is a brand-name biologic medication prescribed for certain rare autoimmune disorders. Dosing of Ultomiris is done via intravenous (IV) infusions administered by a healthcare professional.

When it comes to new drugs, how much are we willing to pay for innovation? That question, touched on by Craig Garthwaite and Benedic Ippolito in their First Opinion on drug prices, deserves a deeper ...

Ultomiris is administered intravenously by a healthcare professional, with infusion times varying from 24 to 90 minutes or more depending on the dose. The dosage of Ultomiris is determined by body ...